HomeCompareALXEF vs PFE

ALXEF vs PFE: Dividend Comparison 2026

ALXEF yields 9756.10% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALXEF wins by $43230381229833840.00M in total portfolio value
10 years
ALXEF
ALXEF
● Live price
9756.10%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43230381229833840.00M
Annual income
$42,375,942,331,967,610,000,000.00
Full ALXEF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ALXEF vs PFE

📍 ALXEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALXEFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALXEF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALXEF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALXEF
Annual income on $10K today (after 15% tax)
$829,268.29/yr
After 10yr DRIP, annual income (after tax)
$36,019,550,982,172,465,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ALXEF beats the other by $36,019,550,982,172,465,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALXEF + PFE for your $10,000?

ALXEF: 50%PFE: 50%
100% PFE50/50100% ALXEF
Portfolio after 10yr
$21615190614916920.00M
Annual income
$21,187,971,165,983,804,000,000.00/yr
Blended yield
98.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ALXEF
No analyst data
Altman Z
21.7
Piotroski
0/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALXEF buys
0
PFE buys
0
No recent congressional trades found for ALXEF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALXEFPFE
Forward yield9756.10%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$43230381229833840.00M$49.6K
Annual income after 10y$42,375,942,331,967,610,000,000.00$26,258.71
Total dividends collected$43173501257510792.00M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALXEF vs PFE ($10,000, DRIP)

YearALXEF PortfolioALXEF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$986,310$975,609.76$9,153$693.39+$977.2KALXEF
2$90,985,578$89,930,226.22$8,593$849.25+$90.98MALXEF
3$7,850,557,226$7,753,202,657.96$8,336$1,066.78+$7850.55MALXEF
4$633,609,188,528$625,209,092,296.54$8,437$1,384.80+$633609.18MALXEF
5$47,836,734,147,594$47,158,772,315,868.44$9,013$1,875.40+$47836734.14MALXEF
6$3,378,690,702,500,742$3,327,505,396,962,816.50$10,306$2,680.72+$3378690702.49MALXEF
7$223,260,494,299,726,370$219,645,295,248,050,560.00$12,820$4,101.38+$223260494299.71MALXEF
8$13,803,319,479,942,732,000$13,564,430,751,042,025,000.00$17,673$6,826.70+$13803319479942.71MALXEF
9$798,541,026,043,208,800,000$783,771,474,199,670,000,000.00$27,543$12,591.86+$798541026043208.75MALXEF
10$43,230,381,229,833,840,000,000$42,375,942,331,967,610,000,000.00$49,560$26,258.71+$43230381229833840.00MALXEF

ALXEF vs PFE: Complete Analysis 2026

ALXEFStock

ALX Resources Corp. engages in the acquisition, exploration, and development of mineral properties in Canada. The company explores for nickel, copper, and cobalt minerals totaling approximately 23,624 hectares at its Firebird Nickel Project located in the northern Athabasca region of Saskatchewan. It also holds interest in the Sceptre Gold Project that consists of 12 claims covering an area of 6,226 hectares located in east-central Saskatchewan; and the Hummingbird Gold Project, which includes 12 claims covering an area of 14,097.87 hectares located to the northwest of the town of Stony Rapids, Saskatchewan. Further, it holds 100% interest in the Gibbons Creek Uranium project consists of 7 mineral claims covering 13,864 hectares located on the north edge of the Athabasca Basin, Saskatchewan; the Flying Vee Nickel/Gold project comprises 14 claims totaling 27,622 hectares situated on the north of the Athabasca Basin; Alligator Lake Gold project, which includes 5 claims totaling 2,973.32 hectares located on the northeast of La Ronge, Saskatchewan; Vixen Gold project that consists of 499 mineral claims covering 10,069 hectares situated at the east of Red Lake, Ontario; Cannon copper project covering 117 cell units totaling 2,600 hectares; Draco VMS project comprises 10 claims totaling approximately 5,959 hectares; and Sabre Uranium project comprises 16 mineral claims covering 16,041 hectares situated in Athabasca basin, Saskatchewan. Additionally, the company holds interests in the Javelin Uranium project, consisting of 9 mineral claims totaling 23,652 hectares located in northern Saskatchewan; and the McKenzie Lake Uranium project, comprising 4 mineral claims totaling 6,916 hectares situated in northern Saskatchewan, Canada. The company was formerly known as ALX Uranium Corp. and changed its name to ALX Resources Corp. in January 2020. ALX Resources Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Full ALXEF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ALXEF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALXEF vs SCHDALXEF vs JEPIALXEF vs OALXEF vs KOALXEF vs MAINALXEF vs JNJALXEF vs MRKALXEF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.